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TB remains neglected compared with 
other infectious diseases, even though 
it’s a leading killer in impoverished 
nations. For over a decade, Barry has 
been coaxing people to collaborate in 
the name of TB elimination (1). At the 
NIH, he and his colleagues study the 
metabolism of Mycobacterium tuberculosis 
(Mtb) within the host cell (2). 
Their work has revealed 
ways to suffocate both 
replicating and nonrepli-
cating Mtb with drugs like 
PA-824, which is cur-
rently in clinical trials (3). 
By analyzing the Mtb ge-
nome and the crystal struc-
ture of its proteins, Barry 
has identified how specific molecules 
mediate drug sensitivity (4) and how 
glycolipid antigens manipulate the im-
mune response (5).
MONEY ISN’T THE ONLY HURDLE
Has the funding situation improved for 
TB over the last decade?
Ten years ago it was all talk and no 
money. Now there’s actually money on 
the table.
Do you think the situation will continue 
to improve under the new administration?
There’s certainly been a lot of the right 
noise. I don’t want to guess what will 
happen with the economic stimulus 
package, but for the fi  rst time, the NIH 
is being considered as part of an economic 
stimulus plan. It’s a logical match because 
that money will be spent on research and 
development and it will also create jobs.
Have recent global initiatives calling for TB 
eradication delivered more than rhetoric?
They defi  nitely help. I think we’re grad-
ually learning how to do big science. 
These kinds of eff  orts take a lot of diff  erent 
skill sets, and I think that the real impact 
of the big programs from the Gates 
Foundation,  NIH, and the European 
Union is to bring together people who 
might not otherwise collaborate. 
Is the mouse model suffi   cient for human 
drug design?
That depends on who you ask [laughs]. 
The problem is that our pathway to 
develop drugs in the past has always 
gone through mice. So it’s no surprise 
that when you look at existing drugs, 
the mice predict how the drug acts in 
humans, because otherwise they wouldn’t 
have been used in the fi  rst place. It’s a 
self-fulfi  lling prophecy.
My bias is that the human disease 
looks nothing like the mouse disease. 
Pathologically, you don’t see the same 
spectrum of lesions. Mice don’t even 
normally get tuberculosis, and so it’s 
not a great leap of logic to say that drug 
activities will differ between the two.
What’s so tricky about developing a TB 
vaccine?
All the vaccinologists will accuse me of 
using this as a cop-out answer, but I’ll say 
it anyway. One of the trickiest things 
about TB is that there is no natural 
immunity to reinfection. People get 
reinfected all the time. I think if exposure 
to the normal bacteria doesn’t confer 
any protective advantage on the host, 
then you’re going to have to do some-
thing better than the immune system 
normally does.   And that’s a tall order.
Do you think academics devote too much 
attention to fundamental research and 
too little time searching for promising 
drug targets?
Yes, but then I’d also turn around and 
criticize the industry people for doing 
too much preclinical research and not 
enough fundamental research. I think 
there are big conceptual gaps in under-
standing what is an eff  ective target and 
what is an appropriate intervention 
point. I can’t tell you how many times 
I’ve been approached by industry people 
who want to do something for TB and 
say, “Just give us a target and we’ll design 
you an inhibitor with drug-like qualities.” 
And I’ll turn to them and say, “If I had a 
good target, this problem would be over.”
ONE BYZANTINE BUG
One-third of the global population carries 
latent TB. How important is it to reduce 
that number?
Latent disease is a funny concept. People 
have historically considered TB to have 
two states, latent or active, meaning the 
bacteria is replicating or not replicating. 
But there seems to be a spectrum of 
disease states, where we have everything 
from genuinely sterile scars of infection 
to permanent disease. As the defi  nition 
stands, when we say latency, we mean 
that a person has no signs or symptoms 
of tuberculosis, but they have a de-
layed-type hypersensitivity response to 
subcutaneous implanted antigen from 
tuberculosis. All that says is that a person 
has seen the antigen before, but they’re 
not sick.
But if you look at those patients 
carefully, some may have been exposed 
to the disease decades ago and their 
immune system took care of it. Whereas 
other patients have clinical disease but 
it’s developing slowly. You won’t find 
bacteria in their sputum, they’re not 
running a fever, no night sweats, no 
classical signs of tuberculosis—but they 
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are on their way. What I’m interested in 
is trying to understand how to identify 
people who are truly at risk for the 
disease, so we can treat them with the 
appropriate prophylaxis.
Has decoding the Mycobacterium 
tuberculosis (Mtb) genome led to new 
drugs?
I don’t think there’s any example in 
the drug area yet. There certainly is in 
the diagnostics area. There’s a test 
called QuantiFERON that’s now 
FDA-approved for diagnosing TB in 
lieu of doing the classical PPD test.
Drug-wise, it’s a complicated situa-
tion. Everybody asks the same questions: 
What are the essential genes? I think I’ll 
go to my grave at this point saying there’s 
no such thing as a nonessential gene, we 
just don’t understand when it’s essential.
What about genetic redundancy?
I struggle with the concept of redun-
dancy. For example, the Leprosy bacillus 
has lost the ability to grow outside of 
a human being. And as a consequence, 
although it’s closely related to Mtb, it 
has lost more than half of its genes because 
it doesn’t need them when growing 
inside a human. If there were really 
completely redundant genes, Mtb 
would’ve undergone the same process. 
So I think at some point in its life cycle, 
although we may not understand 
when that point is or what those con-
ditions are, virtually every 
gene is essential.
I completely discount 
the idea that you should 
prioritize things based on 
what is essential for aerobic 
growth on glucose in a lab-
oratory. But people don’t 
like that idea, because they 
like to keep it simple.
People respond diff  erently to 
Mtb infection, is that on 
account of variation in the 
human genome or variation in 
the bacterial genome?
I think both. Every two 
months we hear about a new 
genetic polymorphism that’s associated 
with TB in this population or that 
population. But what we miss when 
we consider it just from the human 
side is that the bacteria are evolving—
probably faster than we are. And so 
when we measure human genetic sus-
ceptibility, those genes may have been 
selected by the bacterial strain that 
was prevalent in the area 20 years before. 
Mtb has evolved virulence attributes—
it’s not just constructed of simple 
things like proteins but complex lipids.
What makes a lipid-laden bacterium so 
special?
Let me give you one example: The 
phenolic glycolipid of TB is expressed 
in the Beijing strains—which every-
one thinks are hyper-virulent—while 
in many other strain types they’re not 
expressed at all. These lipids are surface 
exposed, they’re glycosylated, and 
they’re obviously important. If we take 
a strain expressing [phenolic glycolipid] 
in the mouse, we get mortality in that 
mouse very rapidly. If the only thing 
we genetically change in the strain is 
blocking production of that lipid, the 
mice live as though they weren’t in-
fected. And so we know [the lipid] is 
interacting with the immune system, 
and we know that it’s variable in strains 
that are circulating globally. We just 
don’t know what the impact is on actual 
disease progression.
A CHEMICAL ATTRACTION
You’re active in TB policy, serving as an 
advisor to the Global Alliance for TB Drug 
Development and the World Health 
Organization. Why take on the extra work?
It was something I wanted to do. I was 
drawn into the bigger picture 
because it helped me to 
understand what we needed 
to do in the laboratory to 
really make something use-
ful to people who treat and 
diagnose TB.
What were you doing before 
you got into tuberculosis?
I was working on Chlamydia 
right before I got into TB.
Why did you switch?
It was kind of switching back, actually, 
because I came out of a chemistry back-
ground. I did my graduate work at Cor-
nell in a chemically oriented laboratory, 
and then a postdoc at Johns Hopkins in 
another chemically oriented laboratory. 
I had gotten frustrated with just doing 
the chemistry; I wanted to be able to do 
some of the biology, too.
How is chemistry related to your switch 
from Chlamydia to TB?
Ah, you have to appreciate it from a 
chemist’s perspective. If you’re a chemist 
looking into bacterial diseases, and you 
see that TB has these amazing, 80-carbon-
long lipids with cyclopropanes 
and all of this fancy chemical 
decoration, you say, “Wow, 
what a bug.” And that was 
before I even really knew 
how important TB was.
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